You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 86 No. 3, March 1963 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (7)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Induced Fibrinolytic Activity and Hypofibrinogenemia

Effect of Epsilon-Amino-Caproic Acid

JOHN S. BELKO, B.S.; RICHARD WARREN, M.D.; ELLEN E. REGAN, B.A.; ROBERT G. SIMPSON

AMA Arch Surg. 1963;86(3):396-401.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The introduction of therapeutic preparations that produce a fibrinolytic state has created a need for a neutralizing agent or inhibitor that can be used in any emergency in the event of hemorrhage resulting from over-dosage of the drugs or hypersensitivity to them.

In 1953, De Vries6 demonstrated the activity of amino acids as inhibitors of fibrinolytic activity. In 1959 Okamoto and his co-workers15 published an account of their earlier discovery of {varepsilon}-amino-caproic acid (EACA) as a potent inhibitor of fibrinolysis. They named the product Ipsilon.5,21 Sarker,19 Sjoerdsma,20 Ablondi,2 and Alkjaersig3 substantiated these findings.

The mechanism of inhibition of lysis by {varepsilon}-amino-caproic acid has been shown to be one of preventing the activation of plasminogen rather than the neutralization of fibrinolytic activity of plasmin.1-3,10,8

The creation of a bleeding state in dogs by the use of plasmin or an activator, and its subsequent . . . [Full Text PDF of this Article]


Author Affiliations

WEST ROXBURG, MASS.

Chemist, Research Laboratory, Veterans Administration Hospital (Mr. Belko); Chief, Surgical Service, Veterans Administration Hospital, and Clinical Professor of Surgery, Harvard Medical School (Dr. Warren).; From the Department of Surgery, Harvard Medical School and the Surgical Service, Veterans Administration Hospital.


Footnotes

Submitted for publication Sept. 4, 1962.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1963 American Medical Association. All Rights Reserved.